Table 1.
Demographics and illness-related data.
| - | Total Sample (N = 100) | Schizophrenia Spectrum Disorders (N = 69) | Bipolar Spectrum Disorders (N = 31) | |
|---|---|---|---|---|
| Demographic Data | ||||
| Median age | 47 (IQR: 37–55) | 45 (IQR: 36–53) | 52 (IQR: 37–58) | |
| Sex * | Female | 39 | 21 (30%) | 18 (58%) |
| Male | 61 | 48 (70%) | 13 (42%) | |
| Education | Primary school | 10 | 9 (12%) | 1 (3%) |
| Secondary school | 35 | 25 (36%) | 10 (32%) | |
| High school | 43 | 29 (42%) | 14 (45%) | |
| Higher education | 12 | 6 (9%) | 6 (19%) | |
|
Marital
Status * |
Unmarried | 72 | 54 (78%) | 18 (58%) |
| Married | 28 | 15 (22%) | 13 (42%) | |
| Employment status | Unemployed | 75 | 51 (74%) | 24 (77%) |
| Employed | 25 | 18 (26%) | 7 (23%) | |
| Smoking status | Non-smokers | 50 | 33 (48%) | 17 (55%) |
| Smokers | 50 | 36 (52%) | 14 (45%) | |
| Concomitant pathologies | Dysthyroidism | 9 | 7 (10%) | 2 (6%) |
| Diabetes | 8 | 7 (10%) | 1 (3%) | |
| Hypertension | 14 | 8 (12%) | 6 (19%) | |
|
Hyper-
cholesterolemia |
7 | 5 (7%) | 2 (6%) | |
| Illness-related data | ||||
| GASS total | 13 (IQR: 6–21) | 13 (IQR: 6–21) | 13 (IQR: 6–20) | |
| UKU total + | 6 (IQR: 3–10) | 6 (IQR: 3–10) | 6 (IQR: 4–10) | |
|
Median illness
duration in years |
13 (IQR: 5–20) | 11 (IQR: 5–20) | 15 (IQR: 6–20) | |
|
Median lifetime
hospitalizations |
2 (IQR: 0–3) | 1 (IQR: 0–3) | 2 (IQR: 1–4) | |
| Median olanzapine oral equivalents in milligrams | 12.33 (IQR: 8–19) | 13.3 (IQR: 8–20) | 10 (IQR: 5–15) | |
| Antipsychotics administration route | Oral | 73 | 49 (71%) | 24 (77.5%) |
| Injection | 15 | 10 (14.5%) | 5 (16%) | |
| Oral plus injection | 12 | 10 (14.5%) | 2 (6.5%) | |
| Mono/polypharmacy | Monotherapy | 71 | 47 (68%) | 24 (77%) |
| Polytherapy | 29 | 22 (32%) | 7 (23%) | |
| Concomitant psychotropics | Mood stabilizers * | 49 | 24 (35%) | 25 (81%) |
| Antidepressants | 36 | 21 (30%) | 15 (48%) | |
| Benzodiazepines * | 41 | 22 (32%) | 19 (61%) | |
| Setting * | Outpatient | 90 | 65 (94%) | 25 (81%) |
| Inpatient | 10 | 4 (6%) | 6 (19%) | |
IQR: interquartile ranges; GASS: Glasgow Antipsychotic Side Effect Scale; UKU: Udvalg for Kliniske Undersøgelser (UKU) side-effects scale; * Schizophrenia and bipolar spectrum significantly differ for these variables; + only the items corresponding to the GASS were considered for the computation.